- Home
- KPRX vs SNSE Comparison
KPRX vs SNSE Comparison
Compare KPRX & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- SNSE
- Stock Information
- Founded
- KPRX 1998
- SNSE 2005
- Country
- KPRX United States
- SNSE United States
- Employees
- KPRX N/A
- SNSE N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- SNSE Biotechnology: Pharmaceutical Preparations
- Sector
- KPRX Health Care
- SNSE Health Care
- Exchange
- KPRX Nasdaq
- SNSE Nasdaq
- Market Cap
- KPRX 9.1M
- SNSE 9.3M
- IPO Year
- KPRX N/A
- SNSE 2021
- Fundamental
- Price
- KPRX $2.90
- SNSE $8.69
- Analyst Decision
- KPRX Strong Buy
- SNSE Strong Buy
- Analyst Count
- KPRX 1
- SNSE 3
- Target Price
- KPRX $10.00
- SNSE $86.67
- AVG Volume (30 Days)
- KPRX 1.3M
- SNSE 12.2K
- Earning Date
- KPRX 08-08-2025
- SNSE 08-05-2025
- Dividend Yield
- KPRX N/A
- SNSE N/A
- EPS Growth
- KPRX N/A
- SNSE N/A
- EPS
- KPRX N/A
- SNSE N/A
- Revenue
- KPRX $20,000.00
- SNSE N/A
- Revenue This Year
- KPRX N/A
- SNSE N/A
- Revenue Next Year
- KPRX N/A
- SNSE N/A
- P/E Ratio
- KPRX N/A
- SNSE N/A
- Revenue Growth
- KPRX N/A
- SNSE N/A
- 52 Week Low
- KPRX $2.51
- SNSE $5.00
- 52 Week High
- KPRX $4.86
- SNSE $17.40
- Technical
- Relative Strength Index (RSI)
- KPRX 43.33
- SNSE 63.87
- Support Level
- KPRX $2.87
- SNSE $5.86
- Resistance Level
- KPRX $3.22
- SNSE $8.74
- Average True Range (ATR)
- KPRX 0.18
- SNSE 0.75
- MACD
- KPRX -0.02
- SNSE 0.25
- Stochastic Oscillator
- KPRX 5.77
- SNSE 88.54
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).